Cocrystal Pharma rises on starting influenza treatment safety trial

Cocrystal Pharma

10/03/2022 16:00

** Shares of antiviral drug developer Cocrystal Pharma
 COCP.O  rise 1.5% to $0.52
    ** COCP says it dosed the first subjects in an early-stage
trial testing its oral antiviral drug candidate, CC-42344, for
the treatment of influenza A  urn:newsml:reuters.com:*:nGNX7zJXyJ
    ** The study, designed to assess the safety and tolerability
of the antiviral treatment, is expected to enroll up to 56
healthy adults at a single site in Australia
    ** Co also expects to initiate two other first-in-human
trials for its drug candidates for the treatment of COVID-19
this year
    ** Stock down 20% YTD, including session's moves

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))